ログイン

IMMUNOLOGY

IMMUNOLOGY
100問 • 2年前
  • Yves Laure Pimentel
  • 通報

    問題一覧

  • 1

    1. From the following, identify a specific component of the adaptive immune system that is formed in response to antigenic stimulation: * 1/1 A. Lysozyme B. Complement C. Commensal organisms D. Immunoglobulin (Ig)

    D

  • 2

    2. Which two organs are considered the primary lymphoid organs in which immunocompetent cells originate and mature? * A. Thyroid and Peyer patches B. Thymus and bone marrow C. Spleen and mucosal-associated lymphoid tissue (MALT) D. Lymph nodes and thoracic duct

    B

  • 3

    3. What type of B cells is formed after antigen stimulation? * 1/1 A. Plasma cells and memory B cells B. Mature B cells C. Antigen-dependent B cells D. Receptor-activated B cells

    A

  • 4

    4. T cells travel from bone marrow to the thymus for maturation. What is the correct order of the maturation sequence for T cells in the thymus? * 1/1 A. Bone marrow to the cortex; after thymic education, released back to peripheral circulation B. Maturation and selection occur in the cortex; migration to the medulla; release of mature T cells to secondary lymphoid organs C. Storage in either the cortex or medulla; release of T cells into the peripheral circulation D. Activation and selection occur in the medulla; mature T cells are stored in the cortex until activated by antigen

    B

  • 5

    5. Which cluster of differentiation (CD) marker is the most specific identifying marker for mature T cells? * 1/1 A. CD1 B. CD2 C. CD3 D. CD4 or CD8

    C

  • 6

    Which markers are found on mature, peripheral helper T cells? * 1/1 A. CD1, CD2, CD4 B. CD2, CD3, CD8 C. CD1, CD3, CD4 D. CD2, CD3, CD4

    D

  • 7

    . Which T cells express the CD8 marker and act specifically to kill tumors or virally infected cells? * 1/1 A. Helper T cells B. Suppressor T cells C. Cytotoxic T cells (TC cells) D. Regulator T cells

    C

  • 8

    8. How are TC cells and natural killer (NK) cells similar? * 1/1 A. Require antibody to be present B. Effective against virally infected cells C. Recognize antigen in association with human leukocyte antigen (HLA) class II markers D. Do not bind to infected cells

    B

  • 9

    9. What is the name of the process by which phagocytic cells are attracted to a substance, such as a bacterial peptide? * 1/1 A. Diapedesis B. Degranulation C. Chemotaxis D. Phagotaxis

    C

  • 10

    10. All of the following are immunologic functions of complement except: * 1/1 A. Induction of an antiviral state B. Opsonization C. Chemotaxis D. Anaphylatoxin formation

    A

  • 11

    11. Which complement component is found in both the classic and alternative pathways? * 1/1 A. C1 B. C4 C. Factor D D. C3

    D

  • 12

    12. Which Ig(s) help(s) initiate the classic complement pathway? * 1/1 A. IgA and IgD B. IgM only C. IgG and IgM D. IgG only

    C

  • 13

    13. How is complement activity destroyed in vitro? * 1/1 A. Heating serum at 56°C for 30 minutes B. Keeping serum at room temperature of 22°C for 1 hour C. Heating serum at 37°C for 45 minutes D. Freezing serum at 0°C for 24 hours

    A

  • 14

    14. What is the purpose of C3a, C4a, and C5a, the split products of the complement cascade? * 0/1 A. To bind with specific membrane receptors of lymphocytes and cause release of cytotoxic substances B. To cause increased vascular permeability, contraction of smooth muscle, and release of histamine from basophils C. To bind with membrane receptors of macrophages to facilitate phagocytosis and the removal of debris and foreign substances D. To regulate and degrade membrane cofactor protein after activation by C3 convertase

    B

  • 15

    15. Which region of the Ig molecule can bind antigen? * 1/1 A. Fragment antigen binding (Fab) B. Fragment crystallizable (Fc) C. Constant light (CL) D. Constant heavy (CH)

    A

  • 16

    16. Which region determines whether an Ig molecule can fix complement? * 0/1 A. Variable heavy (VH) B. Constant heavy (CH) C. Variable light (VL) D. Constant light (CL)

    B

  • 17

    17. Which Ig class(es) has (have) a J-chain? * 1/1 A. IgM B. IgE and IgD C. IgM and surface IgA (sIgA) D. IgG3 and IgA

    C

  • 18

    18. Which Ig appears first in the primary immune response? * 1/1 A. IgG B. IgM C. IgA D. IgE

    B

  • 19

    19. Which immunoglobulin appears in highest titer in the secondary response? * 0/1 A. IgG B. IgM C. IgA D. IgE

    A

  • 20

    20. Which Ig can cross the placenta? * 1/1 A. IgG B. IgM C. IgA D. IgE

    A

  • 21

    21. Which Ig cross-links mast cells to release histamine? * 1/1 A. IgG B. IgM C. IgA D. IgE

    D

  • 22

    22. All of the following are functions of Igs except: * 0/1 A. Neutralizing toxic substances B. Facilitating phagocytosis through opsonization C. Interacting with TC cells to lyse viruses D. Combining with complement to destroy cellular antigens

    C

  • 23

    23. Which of the following cell surface molecules is classified as an MHC class II antigen? * 1/1 A. HLA-A B. HLA-B C. HLA-C D. HLA-DR

    D

  • 24

    24. Which MHC class of molecule is necessary for antigen recognition by CD4-positive T cells? * 1/1 A. Class I B. Class II C. Class III D. No MHC molecule is necessary for antigen recognition

    B

  • 25

    25. Which of the following are products of HLA class III genes? * 1/1 A. T-cell immune receptors B. HLA-D antigens on immune cells C. Complement proteins C2, C4, and factor B D. Ig VL regions

    C

  • 26

    26. What molecule on the surface of most T cells recognizes antigen? * 1/1 A. IgT, a four-chain molecule that includes the tau heavy chain B. MHC protein, a two-chain molecule encoded by the HLA region C. CD3, consisting of six different chains D. T-cell receptor (TcR), consisting of two chains: α-chain and β-chain

    D

  • 27

    27. TcR is similar to Ig molecules in that it: * 0/1 A. Remains bound to the cell surface and is never secreted B. Contains V and C regions on each of its chains C. Binds complement D. Can cross the placenta and provide protection to a fetus

    B

  • 28

    28. Toll-like receptors (TLRs) are found on which cells? * 1/1 A. T cells B. Dendritic cells C. B cells D. Large granular lymphocytes

    B

  • 29

    29. Macrophages produce which of the following proteins during antigen processing? * 1/1 A. IL-1 and IL-6 B. γ-Interferon C. IL-4, IL-5, and IL-10 D. Complement components C1 and C3

    A

  • 30

    30. A superantigen, such as toxic shock syndrome toxin-1 (TSST-1), bypasses the normal antigen-processing stage by binding to and cross-linking: * 1/1 A. A portion of an Ig molecule and complement component C1 B. TLRs and an MHC class 1 molecule C. A portion of an Ig and a portion of a TcR D. A portion of a TcR and an MHC class II molecule

    D

  • 31

    31. T-regulator cells, responsible for controlling autoimmune antibody production, express which of the following phenotypes? * 0/1 A. CD3, CD4, CD8 B. CD3, CD8, CD25 C. CD3, CD4, CD25 D. CD8, CD25, CD56

    C

  • 32

    1. The interaction between individual antigen and antibody molecules depends on several types of bonds, such as ionic bonds, hydrogen bonds, hydrophobic bonds, and van der Waals forces. How is the strength of this attraction characterized? * 1/1 A. Avidity B. Affinity C. Reactivity D. Valency

    B

  • 33

    2. A laboratory is evaluating an enzyme-linked immunosorbent assay (ELISA) for detecting an antibody to cyclic citrullinated peptide (CCP), which is a marker for rheumatoid arthritis (RA). The laboratory includes serum from healthy volunteers and from patients with other connective tissue diseases in the evaluation. These specimens determine which factor of the assay? * 1/1 A. Sensitivity B. Precision C. Bias D. Specificity

    D

  • 34

    3. The detection of precipitation reactions depends on the presence of optimal proportions of antigen and antibody. A patient’s sample contains a large amount of antibody, but the reaction in a test system containing antigen is negative. What has happened? * 1/1 A. Performance error B. Low specificity C. A shift in the zone of equivalence D. Prozone phenomenon

    D

  • 35

    4. The positive and negative control values for an ELISA procedure are below their acceptable ranges. What is the most likely cause? * 0/1 A. Decay of the positive and negative controls B. Incomplete washing following specimen addition C. Overly long incubation times D. Decay of the antibody–enzyme conjugate

    D

  • 36

    5. What is the interpretation when an Ouchterlony plate shows crossed lines between wells 1 and 2 (antigen is placed in the center well and antisera in wells 1 and 2)? * 1/1 A. No reaction between wells 1 and 2 B. Partial identity between wells 1 and 2 C. Nonidentity between wells 1 and 2 D. Identity between wells 1 and 2

    C

  • 37

    6. A weight lifter taking many supplements is tested monthly for thyroid-stimulating hormone (TSH) in a direct capture assay, which uses a streptavidin–biotin indicator system. She has had normal TSH levels for the past 3 months on specimens collected in the late evening. This month she comes in right after breakfast for her blood draw. The TSH level is three times her previous level. What may be the cause of this difference? * 0/1 A. Diurnal variation in TSH levels B. Exogenous biotin in her system from a supplement taken that morning C. Reduced thyroid function caused by an unidentified pathology D. Pipetting error

    B

  • 38

    7. What comprises the indicator system in an indirect ELISA for detecting antibody? * 0/1 A. Enzyme-conjugated antibody + chromogenic substrate B. Enzyme conjugated antigen + chromogenic substrate C. Enzyme + antigen D. Substrate + antigen

    A

  • 39

    8. What outcome results from improper washing of a tube or well after adding the enzyme–antibody conjugate in an ELISA system? * 1/1 A. Result will be falsely decreased B. Result will be falsely increased C. Result will be unaffected D. Result is impossible to determine

    A

  • 40

    9. What would happen if the color reaction phase is prolonged in one tube or well of an ELISA test? * 1/1 A. Result will be falsely decreased B. Result will be falsely increased C. Result will be unaffected D. Impossible to determine

    B

  • 41

    10. The absorbance of a sample measured by ELISA is greater than the highest standard. What corrective action should be taken? * 1/1 A. Extrapolate an estimated value from the highest reading B. Repeat the test using a standard of higher concentration C. Repeat the assay using one half the volume of the sample D. Dilute the test sample

    D

  • 42

    11. A patient was suspected of having a lymphoproliferative disorder. After several laboratory tests were completed, the patient was found to have an IgMκ paraprotein. In what sequence should the laboratory tests leading to this diagnosis have been performed? * 1/1 A. Serum protein electrophoresis (SPE) followed by immunofixation electrophoresis (IFE) B. Ig levels, followed by SPE C. Total lymphocyte count, followed by Ig levels D. Ig levels, followed by urine protein electrophoresis

    A

  • 43

    12. An IFE performed on a serum sample showed a narrow dark band in the lanes containing anti-γ and anti-λ. How should this result be interpreted? * 1/1 A. Abnormally decreased IgG concentration B. Abnormal test result demonstrating monoclonal IgGλ C. Normal test result D. Impossible to determine without densitometric quantitation

    B

  • 44

    13. Which type of nephelometry is used to measure immune complex formation almost immediately after reagent has been added? * 0/1 A. Rate B. Endpoint C. Continuous D. One-dimensional

    A

  • 45

    14. An antinuclear antibody (ANA) test was performed by using immunofluorescence microscopy assay (IFA), and a clinically significant pattern and titer were reported. Positive and negative controls performed as expected. However, the clinical evaluation of the patient was not consistent with the reported pattern. What is the most likely explanation for this situation? * 0/1 A. The clinical condition of the patient changed since the sample was tested B. The pattern of fluorescence was misinterpreted C. The control results were misinterpreted D. The wrong cell line was used for the test

    B

  • 46

    15. What corrective action should be taken when a specific pattern cannot be identified in a specimen with a positive ANA IFA? * 1/1 A. Repeat the test using a larger volume of sample B. Call the physician C. Have another medical laboratory scientist read the slide D. Dilute the sample and retest

    D

  • 47

    16. Which statement best describes passive agglutination reactions used for serodiagnosis? * 1/1 A. Such agglutination reactions are more rapid because they are a single-step process B. Reactions require the addition of a second antibody C. Passive agglutination reactions require biphasic incubation D. Carrier particles for antigen, such as latex particles, are used

    D

  • 48

    17. What has happened in a titer, if tube Nos. 5 to 7 show a stronger reaction than tube Nos.1 to 4? * 1/1 A. Prozone reaction B. Postzone reaction C. Equivalence reaction D. Poor technique

    A

  • 49

    18. What is the titer in tube No. 8 if tube No. 1 is undiluted and dilutions are doubled? * 0/1 A. 64 B. 128 C. 256 D. 512

    B

  • 50

    9. The directions for a slide agglutination test instruct that after mixing the patient’s serum and antigen-coated latex particles, the slide must be rotated for 2 minutes. What would happen if the slide were rotated for 10 minutes? * 0/1 A. Possible false-positive result B. Possible false-negative result C. No effect D. Depends on the amount of antibody present in

    A

  • 51

    20. Which outcome indicates a negative result in a complement fixation test? * 0/1 A. Hemagglutination B. Absence of hemagglutination C. Hemolysis D. Absence of hemolysis

    C

  • 52

    21. What effect does selecting the wrong gate have on the results when cells are counted by flow cytometry? * 0/1 A. No effect B. Failure to count the desired cell population C. Falsely elevated results D. Impossible to determine

    B

  • 53

    22. Which statement best describes immunophenotyping? * 0/1 A. Lineage determination by detecting antigens on the surface of the gated cells by using fluorescent antibodies B. Identification of cell maturity by using antibodies to detect antigens within the nucleus C. Identification and sorting of cells by front and side scatter of light from a laser D. Analysis of cells collected by flow cytometry by using traditional agglutination reactions

    A

  • 54

    23. A flow cytometry scattergram of a bone marrow sample shows a dense population of cells located in-between normal lymphoid and normal myeloid cells. What is the most likely explanation? * 0/1 A. The sample was improperly collected B. An abnormal cell population is present C. The laser optics are out of alignment D. The cells are most likely not leukocytes

    B

  • 55

    1. Which serum antibody response usually characterizes the primary (early) stage of syphilis? * 1/1 A. Antibodies against syphilis are undetectable B. Detected 1 to 3 weeks after appearance of the primary chancre C. Detected in 50% of cases before the primary chancre disappears D. Detected within 2 weeks after infection

    B

  • 56

    2. What substance is detected in the sample by the rapid plasma reagin (RPR) and Venereal Disease Research Laboratory (VDRL) tests for syphilis? * 0/1 A. Cardiolipin B. Anticardiolipin antibody (ACA) C. Anti–Treponema pallidum antibody D. T. pallidum

    B

  • 57

    3. What type of antigen is used in the RPR card test? * 1/1 A. Live treponemal organisms B. Killed suspension of treponemal organisms C. Cardiolipin D. Tanned sheep cells

    C

  • 58

    4. Which of the following is the most sensitive test to detect congenital syphilis? * 1/1 A. VDRL B. RPR C. T. pallidum particle agglutination (TP-PA) D. Polymerase chain reaction (PCR)

    D

  • 59

    5. A biological false-positive reaction is least likely with which test for syphilis? * 1/1 A. VDRL B. TP-PA C. RPR D. All are equally likely to yield a false-positive result

    B

  • 60

    6. A 12-year old girl has symptoms of fatigue and localized lymphadenopathy. Laboratory tests reveal peripheral blood lymphocytosis, positive RPR, and positive spot test for IM. What test should be performed next? * 0/1 A. HIV screen B. VDRL C. Epstein-Barr virus (EBV)–specific antigen test D. TP-PA test

    D

  • 61

    7. Which test is most likely to be positive in the tertiary stage of syphilis? * 0/1 A. Treponemal-specific antibody B. RPR C. VDRL D. Reagin screen test (RST)

    a

  • 62

    8. What is the most likely interpretation of the following syphilis serological results? RPR: reactive; TP-PA: nonreactive * 0/1 A. Neurosyphilis B. Secondary syphilis C. Syphilis that has been successfully treated D. Biological false positive

    D

  • 63

    9. Which specimen is the sample of choice to evaluate latent or tertiary syphilis? * 1/1 A. Serum sample B. Chancre fluid C. Cerebrospinal fluid (CSF) D. Joint fluid

    C

  • 64

    10. Interpret the following quantitative RPR test results. RPR titer: weakly reactive—1:4; reactive—1:8 to 1:64 * 0/1 A. Excess antibody, prozone effect B. Excess antigen, postzone effect C. Equivalence of antigen and antibody D. Impossible to interpret; testing error

    A

  • 65

    11. Tests to identify infection with HIV fall into which three general classification types of tests? * 0/1 A. Tissue culture, antigen, and antibody tests B. Tests for antigens, antibodies, and nucleic acid C. DNA probe, DNA amplification, and Western blot tests D. ELISA, Western blot, and Southern blot tests

    B

  • 66

    12. Which tests are considered screening tests for HIV? * 1/1 A. ELISA, chemiluminescent, and rapid antibody tests B. IFA, Western blot, radioimmunoprecipitation assay C. Culture, antigen capture assay, DNA amplification D. Reverse transcriptase and messenger RNA (mRNA) assay

    A

  • 67

    13. Which tests are the recommended confirmatory tests for HIV? * 1/1 A. ELISA and rapid antibody tests B. HIV-1,2 antibody differentiation assays, and qualitative PCR test C. Culture, antigen capture assay, quantitative PCR D. Reverse transcriptase and mRNA assay

    B

  • 68

    14. How do fourth- and fifth-generation HIV tests reduce the time from infection to the test becoming positive? * 1/1 A. They are PCR tests detecting viral RNA B. They detect p24 antigen in addition to HIV antibody C. They detect proviral DNA D. They detect antibodies to more antigens than earlier generations of HIV tests

    B

  • 69

    15. A woman who has had five pregnancies subsequently tests positive for HIV on a fourth-generation assay and is negative on an HIV-1,2 differentiation assay and a follow-up molecular assay. The initial reactivity may be caused by: * 1/1 A. Possible cross-reaction with herpes or EBV antibodies B. Interference from medication C. Cross-reacting antibodies elicited during pregnancy D. Possible technical error; a repeat specimen should be requested

    C

  • 70

    16. Interpret the following results for HIV testing: Fourth-generation ELISA: positive; repeat ELISA: positive; HIV 1,2 antibody differentiation assay: negative; qualitative HIV RNA rtPCR assay: positive * 1/1 A. False-positive fourth-generation assay B. False-negative antibody differentiation assay C. Indeterminate; further testing indicated D. HIV p24 antigen detected on fourth-generation ELISA

    D

  • 71

    17. What is the most likely explanation when antibody tests for HIV are negative but the PCR test is positive? * 1/1 A. Probably not HIV infection B. Patient is in the “window phase” before antibody production C. Tests were performed incorrectly D. Clinical signs may be misinterpreted

    B

  • 72

    18. What criteria constitute the classification system for HIV infection? * 1/1 A. CD4-positive T-cell count and clinical symptoms B. Clinical symptoms, condition, duration, and strength of reactivity on a fourth-generation HIV test C. Presence or absence of lymphadenopathy D. Strong fourth-generation HIV test reactivity and CD8-positive T-cell count

    A

  • 73

    19. What is the main difficulty associated with the development of an HIV vaccine? * 1/1 A. The virus has been difficult to culture; antigen extraction and concentration are extremely laborious B. Human trials cannot be performed C. Different strains of the virus are genetically diverse D. Anti-idiotype antibodies cannot be developed

    C

  • 74

    20. Which CD4:CD8 ratio is most likely in a patient with AIDS? * 0/1 A. 2:1 B. 3:1 C. 2:3 D. 1:3

    D

  • 75

    21. What is the advantage of fourth-generation rapid HIV tests over earlier rapid HIV tests? * 1/1 A. They use recombinant antigens B. They detect multiple strains of HIV C. They detect p24 antigen D. They are quantitative

    C

  • 76

    22. Which method is used to test for HIV infection in infants who are born to HIV-positive mothers? * 1/1 A. ELISA B. Western blot test C. PCR test D. Viral culture

    C

  • 77

    23. What is the most likely cause when a fourth-generation HIV assay is positive for all controls and samples? * 0/1 A. Improper pipetting B. Improper washing C. Improper addition of sample D. Improper reading

    B

  • 78

    24. What constitutes a diagnosis of viral hepatitis? * 1/1 A. Abnormal test results for liver enzymes B. Clinical signs and symptoms C. Positive results for hepatitis markers D. All of these options

    D

  • 79

    25. Which of the following statements regarding infection with hepatitis D virus (HDV) is true? * 0/1 A. Occurs in patients with HIV infection B. Does not progress to chronic hepatitis C. Occurs in patients with hepatitis B virus (HBV) infection D. Is not spread through blood or sexual contact

    C

  • 80

    26. All of the following hepatitis viruses are spread through blood or blood products except: * 1/1 A. Hepatitis A virus (HAV) B. HBV C. HCV D. HDV

    A

  • 81

    27. Which hepatitis B marker is the best indicator of early acute infection? * 1/1 A. Hepatitis B surface antigen (HBsAg) B. Hepatitis B e-antigen (HBeAg) C. Hepatitis B core antibody (anti-HBc) D. Hepatitis B surface antibody (anti-HBs)

    A

  • 82

    28. Which is the first antibody detected in serum after infection with HBV? * 1/1 A. Anti-HBs B. Anti-HBc IgM C. Anti-HBe D. All are detectable at the same time

    B

  • 83

    29. Which antibody persists in low-level carriers of HBV? * 0/1 A. IgM anti-HBc B. IgG anti-HBc C. IgM anti-HBe D. IgG anti-HBs

    B

  • 84

    30. What is the most likely explanation when a patient has clinical signs of viral hepatitis but tests negative for HAV IgM, HBsAg, and HCV antibody? * 1/1 A. Tests were performed improperly B. The patient does not have hepatitis C. The patient may be in the “core window” D. Clinical evaluation was performed improperly

    C

  • 85

    31. Which hepatitis B markers should be performed on blood products? * 1/1 A. HBsAg and anti-HBc B. Anti-HBs and anti-HBc C. HBeAg and HBcAg D. Anti-HBs and HBeAg

    A

  • 86

    32. Which hepatitis antibody confers immunity against reinfection with HBV? * 0/1 A. Anti-HBc IgM B. Anti-HBc IgG C. Anti-HBe D. Anti-HBs

    D

  • 87

    33. Which test, other than serological markers, is most consistently elevated in viral hepatitis? * 0/1 A. Antinuclear antibodies B. Alanine aminotransferase (ALT) C. Absolute lymphocyte count D. Lactate dehydrogenase

    B

  • 88

    34. If only anti-HBs is positive, which of the following can be ruled out? * 0/1 A. HBV vaccination B. Distant past infection with HBV C. Hepatitis B immune globulin (HBIG) injection D. Chronic HBV infection

    D

  • 89

    35. Interpret the following results for EBV infection: IgG and IgM antibodies to viral capsid antigen (VCA) are positive. * 0/1 A. Infection in the past B. Infection with a mutual enhancer virus, such as HIV C. Current infection D. Impossible to interpret; need more information

    C

  • 90

    36. Rapid mono tests use latex particles coated with which of the following? * 0/1 A. Guinea pig antigen B. Beef proteins C. Horse proteins D. Sheep proteins

    B

  • 91

    37. Blood products are tested for which virus before being transfused to newborns? * 1/1 A. EBV B. Human T-lymphotropic virus II (HTLV-II) C. CMV D. HDV

    C

  • 92

    38. What is the endpoint for the antistreptolysin O (ASO) latex agglutination assay? * 1/1 A. Highest serum dilution that shows no agglutination B. Highest serum dilution that shows agglutination C. Lowest serum dilution that shows agglutination D. Lowest serum dilution that shows no agglutination

    B

  • 93

    39. A streptozyme test was performed, but the result was negative, even though the patient showed clinical signs of a streptococcal throat infection. What should be done next? * 1/1 A. Either ASO or anti-deoxyribonuclease B (anti-DNase B) test B. Another streptozyme test using diluted serum C. Antihyaluronidase test D. Wait for 3 to 5 days and repeat the streptozyme test

    A

  • 94

    40. Rapid assays for influenza that utilize specimens obtained from nasopharyngeal swabs detect: * 0/1 A. IgM anti-influenza B. IgA anti-influenza C. IgA–influenza antigen immune complexes D. Influenza nucleoprotein antigens

    D

  • 95

    41. How can interfering cold agglutinins be removed from a test sample? * 0/1 A. Centrifuge the serum and remove the top layer B. Incubate the clot at 1°C to 4°C for several hours and then remove the serum C. Incubate the serum at 56°C in a water bath for 30 minutes D. Use an anticoagulated sample

    B

  • 96

    42. All tubes (dilutions) except the negative control are positive for cold agglutinins. This indicates: * 0/1 A. Contaminated RBCs B. A rare antibody against RBC antigens C. The sample was stored at 4°C prior to separating serum and cells D. Further serial dilution is necessary

    D

  • 97

    43. All positive cold agglutinin tubes remain positive after 37°C incubation except the positive control. What is the most likely explanation for this situation? * 0/1 A. High-titer cold agglutinins B. Contamination of the test system C. Antibody other than cold agglutinins D. Faulty water bath

    C

  • 98

    44. Which increase in antibody titer (dilution) best indicates an acute infection? * 1/1 A. From 1:2 to 1:8 B. From 1:4 to 1:16 C. From 1:16 to 1:256 D. From 1:64 to 1:128

    C

  • 99

    45. Which of the following positive antibody tests may be an indication of recent vaccination or early primary infection for rubella in a patient with no clinical symptoms? * 1/1 A. Only IgG antibodies positive B. Only IgM antibodies positive C. Both IgG and IgM antibodies positive D. Fourfold rise in titer for IgG antibodies

    B

  • 100

    46. Why is laboratory diagnosis difficult in cases of Lyme disease? * 0/1 A. Clinical response may not be apparent upon initial infection; IgM antibody may not be detected until 3 to 6 weeks after the infection. B. Laboratory tests may be designed to detect whole Borrelia burgdorferi, not flagellar antigen found early in infection C. Most laboratory tests are technically demanding and lack specificity D. Antibodies formed initially to B. burgdorferi may cross react in antigen tests for autoimmune diseases

    A

  • HTMLBE

    HTMLBE

    Yves Laure Pimentel · 64問 · 2年前

    HTMLBE

    HTMLBE

    64問 • 2年前
    Yves Laure Pimentel

    PARASITOLOGY

    PARASITOLOGY

    Yves Laure Pimentel · 111問 · 2年前

    PARASITOLOGY

    PARASITOLOGY

    111問 • 2年前
    Yves Laure Pimentel

    other names parasitology

    other names parasitology

    Yves Laure Pimentel · 70問 · 2年前

    other names parasitology

    other names parasitology

    70問 • 2年前
    Yves Laure Pimentel

    CC - 1 LAB. SAFETY, BASIC UNITS, AND CONVERSION FACTOR

    CC - 1 LAB. SAFETY, BASIC UNITS, AND CONVERSION FACTOR

    Yves Laure Pimentel · 61問 · 2年前

    CC - 1 LAB. SAFETY, BASIC UNITS, AND CONVERSION FACTOR

    CC - 1 LAB. SAFETY, BASIC UNITS, AND CONVERSION FACTOR

    61問 • 2年前
    Yves Laure Pimentel

    HISTOPATHOLOGY

    HISTOPATHOLOGY

    Yves Laure Pimentel · 69問 · 2年前

    HISTOPATHOLOGY

    HISTOPATHOLOGY

    69問 • 2年前
    Yves Laure Pimentel

    CC-2 SPECTROPHOTOMETRY

    CC-2 SPECTROPHOTOMETRY

    Yves Laure Pimentel · 100問 · 2年前

    CC-2 SPECTROPHOTOMETRY

    CC-2 SPECTROPHOTOMETRY

    100問 • 2年前
    Yves Laure Pimentel

    CC-3 ELECTROPHORESIS

    CC-3 ELECTROPHORESIS

    Yves Laure Pimentel · 41問 · 2年前

    CC-3 ELECTROPHORESIS

    CC-3 ELECTROPHORESIS

    41問 • 2年前
    Yves Laure Pimentel

    AUBF LAB SAFETY

    AUBF LAB SAFETY

    Yves Laure Pimentel · 87問 · 2年前

    AUBF LAB SAFETY

    AUBF LAB SAFETY

    87問 • 2年前
    Yves Laure Pimentel

    CSF 1

    CSF 1

    Yves Laure Pimentel · 100問 · 2年前

    CSF 1

    CSF 1

    100問 • 2年前
    Yves Laure Pimentel

    CSF 2

    CSF 2

    Yves Laure Pimentel · 82問 · 2年前

    CSF 2

    CSF 2

    82問 • 2年前
    Yves Laure Pimentel

    SEMEN 1

    SEMEN 1

    Yves Laure Pimentel · 100問 · 2年前

    SEMEN 1

    SEMEN 1

    100問 • 2年前
    Yves Laure Pimentel

    SEMEN 2

    SEMEN 2

    Yves Laure Pimentel · 7問 · 2年前

    SEMEN 2

    SEMEN 2

    7問 • 2年前
    Yves Laure Pimentel

    SYNOVIAL FLUID 1

    SYNOVIAL FLUID 1

    Yves Laure Pimentel · 100問 · 2年前

    SYNOVIAL FLUID 1

    SYNOVIAL FLUID 1

    100問 • 2年前
    Yves Laure Pimentel

    SYNOVIAL FLUID 2

    SYNOVIAL FLUID 2

    Yves Laure Pimentel · 6問 · 2年前

    SYNOVIAL FLUID 2

    SYNOVIAL FLUID 2

    6問 • 2年前
    Yves Laure Pimentel

    SEROUS FLUID

    SEROUS FLUID

    Yves Laure Pimentel · 25問 · 2年前

    SEROUS FLUID

    SEROUS FLUID

    25問 • 2年前
    Yves Laure Pimentel

    PLEURAL FLUID

    PLEURAL FLUID

    Yves Laure Pimentel · 44問 · 2年前

    PLEURAL FLUID

    PLEURAL FLUID

    44問 • 2年前
    Yves Laure Pimentel

    PERICARDIAL FLUID

    PERICARDIAL FLUID

    Yves Laure Pimentel · 18問 · 2年前

    PERICARDIAL FLUID

    PERICARDIAL FLUID

    18問 • 2年前
    Yves Laure Pimentel

    PERITONEAL FLUID/ ASCITIC FLUID

    PERITONEAL FLUID/ ASCITIC FLUID

    Yves Laure Pimentel · 30問 · 2年前

    PERITONEAL FLUID/ ASCITIC FLUID

    PERITONEAL FLUID/ ASCITIC FLUID

    30問 • 2年前
    Yves Laure Pimentel

    AMNIOTIC FLUID

    AMNIOTIC FLUID

    Yves Laure Pimentel · 92問 · 2年前

    AMNIOTIC FLUID

    AMNIOTIC FLUID

    92問 • 2年前
    Yves Laure Pimentel

    FECALYSIS

    FECALYSIS

    Yves Laure Pimentel · 80問 · 2年前

    FECALYSIS

    FECALYSIS

    80問 • 2年前
    Yves Laure Pimentel

    OTHER BODY FLUIDS

    OTHER BODY FLUIDS

    Yves Laure Pimentel · 89問 · 2年前

    OTHER BODY FLUIDS

    OTHER BODY FLUIDS

    89問 • 2年前
    Yves Laure Pimentel

    MTLBE- SUHO NOTES

    MTLBE- SUHO NOTES

    Yves Laure Pimentel · 86問 · 2年前

    MTLBE- SUHO NOTES

    MTLBE- SUHO NOTES

    86問 • 2年前
    Yves Laure Pimentel

    MTLBE..

    MTLBE..

    Yves Laure Pimentel · 35問 · 2年前

    MTLBE..

    MTLBE..

    35問 • 2年前
    Yves Laure Pimentel

    CC- CHROMATOGRAPHY

    CC- CHROMATOGRAPHY

    Yves Laure Pimentel · 19問 · 1年前

    CC- CHROMATOGRAPHY

    CC- CHROMATOGRAPHY

    19問 • 1年前
    Yves Laure Pimentel

    CC-OSMOMETRY

    CC-OSMOMETRY

    Yves Laure Pimentel · 14問 · 1年前

    CC-OSMOMETRY

    CC-OSMOMETRY

    14問 • 1年前
    Yves Laure Pimentel

    CC-ELECTROCHEMISTRY TECHNIQUES

    CC-ELECTROCHEMISTRY TECHNIQUES

    Yves Laure Pimentel · 43問 · 1年前

    CC-ELECTROCHEMISTRY TECHNIQUES

    CC-ELECTROCHEMISTRY TECHNIQUES

    43問 • 1年前
    Yves Laure Pimentel

    CC- CARBOHYDRATES

    CC- CARBOHYDRATES

    Yves Laure Pimentel · 49問 · 2年前

    CC- CARBOHYDRATES

    CC- CARBOHYDRATES

    49問 • 2年前
    Yves Laure Pimentel

    CC- DIABETES MELLITUS

    CC- DIABETES MELLITUS

    Yves Laure Pimentel · 97問 · 2年前

    CC- DIABETES MELLITUS

    CC- DIABETES MELLITUS

    97問 • 2年前
    Yves Laure Pimentel

    MAJOR LIPOPROTEINS

    MAJOR LIPOPROTEINS

    Yves Laure Pimentel · 57問 · 2年前

    MAJOR LIPOPROTEINS

    MAJOR LIPOPROTEINS

    57問 • 2年前
    Yves Laure Pimentel

    MINOR LIPOPROTEINS

    MINOR LIPOPROTEINS

    Yves Laure Pimentel · 63問 · 2年前

    MINOR LIPOPROTEINS

    MINOR LIPOPROTEINS

    63問 • 2年前
    Yves Laure Pimentel

    PROTEINS

    PROTEINS

    Yves Laure Pimentel · 37問 · 2年前

    PROTEINS

    PROTEINS

    37問 • 2年前
    Yves Laure Pimentel

    PLASMA PROTEINS 1

    PLASMA PROTEINS 1

    Yves Laure Pimentel · 91問 · 2年前

    PLASMA PROTEINS 1

    PLASMA PROTEINS 1

    91問 • 2年前
    Yves Laure Pimentel

    PLASMA PROTEINS 2 (ALPHA 2 REGION)

    PLASMA PROTEINS 2 (ALPHA 2 REGION)

    Yves Laure Pimentel · 98問 · 2年前

    PLASMA PROTEINS 2 (ALPHA 2 REGION)

    PLASMA PROTEINS 2 (ALPHA 2 REGION)

    98問 • 2年前
    Yves Laure Pimentel

    MISCELLANEOUS PROTEINS

    MISCELLANEOUS PROTEINS

    Yves Laure Pimentel · 61問 · 2年前

    MISCELLANEOUS PROTEINS

    MISCELLANEOUS PROTEINS

    61問 • 2年前
    Yves Laure Pimentel

    Liver Function Test 1

    Liver Function Test 1

    Yves Laure Pimentel · 100問 · 2年前

    Liver Function Test 1

    Liver Function Test 1

    100問 • 2年前
    Yves Laure Pimentel

    Liver Function Test 2

    Liver Function Test 2

    Yves Laure Pimentel · 96問 · 2年前

    Liver Function Test 2

    Liver Function Test 2

    96問 • 2年前
    Yves Laure Pimentel

    TUMOR MARKERS

    TUMOR MARKERS

    Yves Laure Pimentel · 33問 · 2年前

    TUMOR MARKERS

    TUMOR MARKERS

    33問 • 2年前
    Yves Laure Pimentel

    KIDNEY FUNCTION TESTS - NON PROTEIN NITROGEN & CREATININE

    KIDNEY FUNCTION TESTS - NON PROTEIN NITROGEN & CREATININE

    Yves Laure Pimentel · 41問 · 2年前

    KIDNEY FUNCTION TESTS - NON PROTEIN NITROGEN & CREATININE

    KIDNEY FUNCTION TESTS - NON PROTEIN NITROGEN & CREATININE

    41問 • 2年前
    Yves Laure Pimentel

    GLYCOGEN STORAGE DISEASES

    GLYCOGEN STORAGE DISEASES

    Yves Laure Pimentel · 17問 · 2年前

    GLYCOGEN STORAGE DISEASES

    GLYCOGEN STORAGE DISEASES

    17問 • 2年前
    Yves Laure Pimentel

    LIPID STORAGE DISEASES

    LIPID STORAGE DISEASES

    Yves Laure Pimentel · 14問 · 2年前

    LIPID STORAGE DISEASES

    LIPID STORAGE DISEASES

    14問 • 2年前
    Yves Laure Pimentel

    PROTEINS

    PROTEINS

    Yves Laure Pimentel · 71問 · 2年前

    PROTEINS

    PROTEINS

    71問 • 2年前
    Yves Laure Pimentel

    QUICK FIRE- ELECTRODES

    QUICK FIRE- ELECTRODES

    Yves Laure Pimentel · 7問 · 2年前

    QUICK FIRE- ELECTRODES

    QUICK FIRE- ELECTRODES

    7問 • 2年前
    Yves Laure Pimentel

    ELECTROLYTES

    ELECTROLYTES

    Yves Laure Pimentel · 10問 · 2年前

    ELECTROLYTES

    ELECTROLYTES

    10問 • 2年前
    Yves Laure Pimentel

    DRUGS

    DRUGS

    Yves Laure Pimentel · 27問 · 2年前

    DRUGS

    DRUGS

    27問 • 2年前
    Yves Laure Pimentel

    TOXIC AGENTS:

    TOXIC AGENTS:

    Yves Laure Pimentel · 12問 · 2年前

    TOXIC AGENTS:

    TOXIC AGENTS:

    12問 • 2年前
    Yves Laure Pimentel

    HEMATOLOGY 1 (HEMATOPOIESIS 1)

    HEMATOLOGY 1 (HEMATOPOIESIS 1)

    Yves Laure Pimentel · 100問 · 2年前

    HEMATOLOGY 1 (HEMATOPOIESIS 1)

    HEMATOLOGY 1 (HEMATOPOIESIS 1)

    100問 • 2年前
    Yves Laure Pimentel

    HEMATOLOGY (HEMATOPOIESIS 2)

    HEMATOLOGY (HEMATOPOIESIS 2)

    Yves Laure Pimentel · 29問 · 2年前

    HEMATOLOGY (HEMATOPOIESIS 2)

    HEMATOLOGY (HEMATOPOIESIS 2)

    29問 • 2年前
    Yves Laure Pimentel

    hema diseases

    hema diseases

    Yves Laure Pimentel · 25問 · 2年前

    hema diseases

    hema diseases

    25問 • 2年前
    Yves Laure Pimentel

    AML

    AML

    Yves Laure Pimentel · 43問 · 2年前

    AML

    AML

    43問 • 2年前
    Yves Laure Pimentel

    GLOBIN SYNTHESIS

    GLOBIN SYNTHESIS

    Yves Laure Pimentel · 71問 · 2年前

    GLOBIN SYNTHESIS

    GLOBIN SYNTHESIS

    71問 • 2年前
    Yves Laure Pimentel

    HEMATOLOGY REFERENCE RANGES

    HEMATOLOGY REFERENCE RANGES

    Yves Laure Pimentel · 31問 · 2年前

    HEMATOLOGY REFERENCE RANGES

    HEMATOLOGY REFERENCE RANGES

    31問 • 2年前
    Yves Laure Pimentel

    DISORDERS OF PRIMARY HEMOSTASIS

    DISORDERS OF PRIMARY HEMOSTASIS

    Yves Laure Pimentel · 34問 · 2年前

    DISORDERS OF PRIMARY HEMOSTASIS

    DISORDERS OF PRIMARY HEMOSTASIS

    34問 • 2年前
    Yves Laure Pimentel

    PLATELET DISORDERS

    PLATELET DISORDERS

    Yves Laure Pimentel · 37問 · 2年前

    PLATELET DISORDERS

    PLATELET DISORDERS

    37問 • 2年前
    Yves Laure Pimentel

    CHARACTERISTICS OF CLOTTING FACTORS

    CHARACTERISTICS OF CLOTTING FACTORS

    Yves Laure Pimentel · 100問 · 2年前

    CHARACTERISTICS OF CLOTTING FACTORS

    CHARACTERISTICS OF CLOTTING FACTORS

    100問 • 2年前
    Yves Laure Pimentel

    4. CLASSIFICATION OF MACROPHAGE

    4. CLASSIFICATION OF MACROPHAGE

    Yves Laure Pimentel · 12問 · 2年前

    4. CLASSIFICATION OF MACROPHAGE

    4. CLASSIFICATION OF MACROPHAGE

    12問 • 2年前
    Yves Laure Pimentel

    3. NATURAL OR INNATE IMMUNITY

    3. NATURAL OR INNATE IMMUNITY

    Yves Laure Pimentel · 39問 · 2年前

    3. NATURAL OR INNATE IMMUNITY

    3. NATURAL OR INNATE IMMUNITY

    39問 • 2年前
    Yves Laure Pimentel

    5. INTERNAL DEFENSE:SOLUBLE FACTORS (ACUTE PHASE REACTANTS)

    5. INTERNAL DEFENSE:SOLUBLE FACTORS (ACUTE PHASE REACTANTS)

    Yves Laure Pimentel · 55問 · 2年前

    5. INTERNAL DEFENSE:SOLUBLE FACTORS (ACUTE PHASE REACTANTS)

    5. INTERNAL DEFENSE:SOLUBLE FACTORS (ACUTE PHASE REACTANTS)

    55問 • 2年前
    Yves Laure Pimentel

    6. PHAGOCYTOSIS Chemotaxis

    6. PHAGOCYTOSIS Chemotaxis

    Yves Laure Pimentel · 37問 · 2年前

    6. PHAGOCYTOSIS Chemotaxis

    6. PHAGOCYTOSIS Chemotaxis

    37問 • 2年前
    Yves Laure Pimentel

    8. NATURE OF ANTIGEN

    8. NATURE OF ANTIGEN

    Yves Laure Pimentel · 44問 · 2年前

    8. NATURE OF ANTIGEN

    8. NATURE OF ANTIGEN

    44問 • 2年前
    Yves Laure Pimentel

    9. MAJOR HISTOCOMPATIBILITY COMPLEX/HUMAN LEUKOCYTE ANTIGEN

    9. MAJOR HISTOCOMPATIBILITY COMPLEX/HUMAN LEUKOCYTE ANTIGEN

    Yves Laure Pimentel · 50問 · 2年前

    9. MAJOR HISTOCOMPATIBILITY COMPLEX/HUMAN LEUKOCYTE ANTIGEN

    9. MAJOR HISTOCOMPATIBILITY COMPLEX/HUMAN LEUKOCYTE ANTIGEN

    50問 • 2年前
    Yves Laure Pimentel

    1. HISTORY

    1. HISTORY

    Yves Laure Pimentel · 69問 · 2年前

    1. HISTORY

    1. HISTORY

    69問 • 2年前
    Yves Laure Pimentel

    2. TYPES OF IMMUNITY

    2. TYPES OF IMMUNITY

    Yves Laure Pimentel · 38問 · 2年前

    2. TYPES OF IMMUNITY

    2. TYPES OF IMMUNITY

    38問 • 2年前
    Yves Laure Pimentel

    7. PHAGOCYTOSIS Engulfment and Digestion

    7. PHAGOCYTOSIS Engulfment and Digestion

    Yves Laure Pimentel · 21問 · 2年前

    7. PHAGOCYTOSIS Engulfment and Digestion

    7. PHAGOCYTOSIS Engulfment and Digestion

    21問 • 2年前
    Yves Laure Pimentel

    8. PHAGOCYTOSIS EXOCYTOSIS

    8. PHAGOCYTOSIS EXOCYTOSIS

    Yves Laure Pimentel · 15問 · 2年前

    8. PHAGOCYTOSIS EXOCYTOSIS

    8. PHAGOCYTOSIS EXOCYTOSIS

    15問 • 2年前
    Yves Laure Pimentel

    10. DISEASE ASSOCIATED TO HUMAN LEUKOCYTE ANTIGEN (henry)

    10. DISEASE ASSOCIATED TO HUMAN LEUKOCYTE ANTIGEN (henry)

    Yves Laure Pimentel · 32問 · 2年前

    10. DISEASE ASSOCIATED TO HUMAN LEUKOCYTE ANTIGEN (henry)

    10. DISEASE ASSOCIATED TO HUMAN LEUKOCYTE ANTIGEN (henry)

    32問 • 2年前
    Yves Laure Pimentel

    11. TRANSPLANTATION IMMUNOLOGY

    11. TRANSPLANTATION IMMUNOLOGY

    Yves Laure Pimentel · 30問 · 2年前

    11. TRANSPLANTATION IMMUNOLOGY

    11. TRANSPLANTATION IMMUNOLOGY

    30問 • 2年前
    Yves Laure Pimentel

    2. LYMPHOID ORGANS

    2. LYMPHOID ORGANS

    Yves Laure Pimentel · 38問 · 2年前

    2. LYMPHOID ORGANS

    2. LYMPHOID ORGANS

    38問 • 2年前
    Yves Laure Pimentel

    3. CLUSTER OF DIFFERENTIATION

    3. CLUSTER OF DIFFERENTIATION

    Yves Laure Pimentel · 48問 · 2年前

    3. CLUSTER OF DIFFERENTIATION

    3. CLUSTER OF DIFFERENTIATION

    48問 • 2年前
    Yves Laure Pimentel

    4. T-CELL DIFFERENTIATION

    4. T-CELL DIFFERENTIATION

    Yves Laure Pimentel · 35問 · 2年前

    4. T-CELL DIFFERENTIATION

    4. T-CELL DIFFERENTIATION

    35問 • 2年前
    Yves Laure Pimentel

    5. T CELL IMMUNODEFICIENCIES

    5. T CELL IMMUNODEFICIENCIES

    Yves Laure Pimentel · 18問 · 2年前

    5. T CELL IMMUNODEFICIENCIES

    5. T CELL IMMUNODEFICIENCIES

    18問 • 2年前
    Yves Laure Pimentel

    6. STAGES IN B-CELL DIFFERENTIATION  PROPIMAP

    6. STAGES IN B-CELL DIFFERENTIATION  PROPIMAP

    Yves Laure Pimentel · 44問 · 2年前

    6. STAGES IN B-CELL DIFFERENTIATION  PROPIMAP

    6. STAGES IN B-CELL DIFFERENTIATION  PROPIMAP

    44問 • 2年前
    Yves Laure Pimentel

    7. B CELL IMMUNODEFICIENCIES

    7. B CELL IMMUNODEFICIENCIES

    Yves Laure Pimentel · 23問 · 2年前

    7. B CELL IMMUNODEFICIENCIES

    7. B CELL IMMUNODEFICIENCIES

    23問 • 2年前
    Yves Laure Pimentel

    8. COMBINED T CELL AND B CELL DEFICIENCIES

    8. COMBINED T CELL AND B CELL DEFICIENCIES

    Yves Laure Pimentel · 34問 · 2年前

    8. COMBINED T CELL AND B CELL DEFICIENCIES

    8. COMBINED T CELL AND B CELL DEFICIENCIES

    34問 • 2年前
    Yves Laure Pimentel

    9. COMPARISON OF T AND B CELLS

    9. COMPARISON OF T AND B CELLS

    Yves Laure Pimentel · 12問 · 2年前

    9. COMPARISON OF T AND B CELLS

    9. COMPARISON OF T AND B CELLS

    12問 • 2年前
    Yves Laure Pimentel

    10. LABORATORY IDENTIFICATION OF LYMPHOCYTES

    10. LABORATORY IDENTIFICATION OF LYMPHOCYTES

    Yves Laure Pimentel · 16問 · 2年前

    10. LABORATORY IDENTIFICATION OF LYMPHOCYTES

    10. LABORATORY IDENTIFICATION OF LYMPHOCYTES

    16問 • 2年前
    Yves Laure Pimentel

    11. NATURAL KILLER CELLS OR THIRD POPULATION CELL

    11. NATURAL KILLER CELLS OR THIRD POPULATION CELL

    Yves Laure Pimentel · 15問 · 2年前

    11. NATURAL KILLER CELLS OR THIRD POPULATION CELL

    11. NATURAL KILLER CELLS OR THIRD POPULATION CELL

    15問 • 2年前
    Yves Laure Pimentel

    12. ANTIBODY

    12. ANTIBODY

    Yves Laure Pimentel · 79問 · 2年前

    12. ANTIBODY

    12. ANTIBODY

    79問 • 2年前
    Yves Laure Pimentel

    13. TYPES OF ANTIBODIES

    13. TYPES OF ANTIBODIES

    Yves Laure Pimentel · 97問 · 2年前

    13. TYPES OF ANTIBODIES

    13. TYPES OF ANTIBODIES

    97問 • 2年前
    Yves Laure Pimentel

    14. MONOCLONAL ANTIBODIES

    14. MONOCLONAL ANTIBODIES

    Yves Laure Pimentel · 11問 · 2年前

    14. MONOCLONAL ANTIBODIES

    14. MONOCLONAL ANTIBODIES

    11問 • 2年前
    Yves Laure Pimentel

    1. INTERLEUKINS

    1. INTERLEUKINS

    Yves Laure Pimentel · 23問 · 2年前

    1. INTERLEUKINS

    1. INTERLEUKINS

    23問 • 2年前
    Yves Laure Pimentel

    2. INTERFERONS

    2. INTERFERONS

    Yves Laure Pimentel · 28問 · 2年前

    2. INTERFERONS

    2. INTERFERONS

    28問 • 2年前
    Yves Laure Pimentel

    3. CYTOKINES IN THE INNATE AND ADAPTIVE IMMUNITY

    3. CYTOKINES IN THE INNATE AND ADAPTIVE IMMUNITY

    Yves Laure Pimentel · 8問 · 2年前

    3. CYTOKINES IN THE INNATE AND ADAPTIVE IMMUNITY

    3. CYTOKINES IN THE INNATE AND ADAPTIVE IMMUNITY

    8問 • 2年前
    Yves Laure Pimentel

    4. COMPLEMENT SYSTEM

    4. COMPLEMENT SYSTEM

    Yves Laure Pimentel · 19問 · 2年前

    4. COMPLEMENT SYSTEM

    4. COMPLEMENT SYSTEM

    19問 • 2年前
    Yves Laure Pimentel

    15. COMPLEMENT SYSTEM

    15. COMPLEMENT SYSTEM

    Yves Laure Pimentel · 76問 · 2年前

    15. COMPLEMENT SYSTEM

    15. COMPLEMENT SYSTEM

    76問 • 2年前
    Yves Laure Pimentel

    16. SYSTEM CONTROLS/COMPLEMENT REGULATION

    16. SYSTEM CONTROLS/COMPLEMENT REGULATION

    Yves Laure Pimentel · 21問 · 2年前

    16. SYSTEM CONTROLS/COMPLEMENT REGULATION

    16. SYSTEM CONTROLS/COMPLEMENT REGULATION

    21問 • 2年前
    Yves Laure Pimentel

    17. COMPLEMENT AND DISEASE STATES

    17. COMPLEMENT AND DISEASE STATES

    Yves Laure Pimentel · 29問 · 2年前

    17. COMPLEMENT AND DISEASE STATES

    17. COMPLEMENT AND DISEASE STATES

    29問 • 2年前
    Yves Laure Pimentel

    18. IMMUNOLOGIC ASSAYS OF INDIVIDUAL COMPONENTS (CLASSICAL)

    18. IMMUNOLOGIC ASSAYS OF INDIVIDUAL COMPONENTS (CLASSICAL)

    Yves Laure Pimentel · 19問 · 2年前

    18. IMMUNOLOGIC ASSAYS OF INDIVIDUAL COMPONENTS (CLASSICAL)

    18. IMMUNOLOGIC ASSAYS OF INDIVIDUAL COMPONENTS (CLASSICAL)

    19問 • 2年前
    Yves Laure Pimentel

    19. CYTOKINES

    19. CYTOKINES

    Yves Laure Pimentel · 22問 · 2年前

    19. CYTOKINES

    19. CYTOKINES

    22問 • 2年前
    Yves Laure Pimentel

    20. INTERLEUKINS

    20. INTERLEUKINS

    Yves Laure Pimentel · 24問 · 2年前

    20. INTERLEUKINS

    20. INTERLEUKINS

    24問 • 2年前
    Yves Laure Pimentel

    21. INTERFERONS, TNF, TGF, CHEMOKINE

    21. INTERFERONS, TNF, TGF, CHEMOKINE

    Yves Laure Pimentel · 21問 · 2年前

    21. INTERFERONS, TNF, TGF, CHEMOKINE

    21. INTERFERONS, TNF, TGF, CHEMOKINE

    21問 • 2年前
    Yves Laure Pimentel

    1. SERO

    1. SERO

    Yves Laure Pimentel · 54問 · 2年前

    1. SERO

    1. SERO

    54問 • 2年前
    Yves Laure Pimentel

    2. PRECIPITATION

    2. PRECIPITATION

    Yves Laure Pimentel · 38問 · 2年前

    2. PRECIPITATION

    2. PRECIPITATION

    38問 • 2年前
    Yves Laure Pimentel

    3. PASSIVE IMMUNODIFFUSION

    3. PASSIVE IMMUNODIFFUSION

    Yves Laure Pimentel · 17問 · 2年前

    3. PASSIVE IMMUNODIFFUSION

    3. PASSIVE IMMUNODIFFUSION

    17問 • 2年前
    Yves Laure Pimentel

    4. OUCHTERLONY

    4. OUCHTERLONY

    Yves Laure Pimentel · 15問 · 2年前

    4. OUCHTERLONY

    4. OUCHTERLONY

    15問 • 2年前
    Yves Laure Pimentel

    5. ELECTROPHORETIC TECHNIQUE

    5. ELECTROPHORETIC TECHNIQUE

    Yves Laure Pimentel · 9問 · 2年前

    5. ELECTROPHORETIC TECHNIQUE

    5. ELECTROPHORETIC TECHNIQUE

    9問 • 2年前
    Yves Laure Pimentel

    6. IMMUNOELECTROPHORESIS (DOUBLE DIFFUSION)

    6. IMMUNOELECTROPHORESIS (DOUBLE DIFFUSION)

    Yves Laure Pimentel · 11問 · 2年前

    6. IMMUNOELECTROPHORESIS (DOUBLE DIFFUSION)

    6. IMMUNOELECTROPHORESIS (DOUBLE DIFFUSION)

    11問 • 2年前
    Yves Laure Pimentel

    7. IMMUNOFIXATION ELECTROPHORESIS

    7. IMMUNOFIXATION ELECTROPHORESIS

    Yves Laure Pimentel · 29問 · 2年前

    7. IMMUNOFIXATION ELECTROPHORESIS

    7. IMMUNOFIXATION ELECTROPHORESIS

    29問 • 2年前
    Yves Laure Pimentel

    問題一覧

  • 1

    1. From the following, identify a specific component of the adaptive immune system that is formed in response to antigenic stimulation: * 1/1 A. Lysozyme B. Complement C. Commensal organisms D. Immunoglobulin (Ig)

    D

  • 2

    2. Which two organs are considered the primary lymphoid organs in which immunocompetent cells originate and mature? * A. Thyroid and Peyer patches B. Thymus and bone marrow C. Spleen and mucosal-associated lymphoid tissue (MALT) D. Lymph nodes and thoracic duct

    B

  • 3

    3. What type of B cells is formed after antigen stimulation? * 1/1 A. Plasma cells and memory B cells B. Mature B cells C. Antigen-dependent B cells D. Receptor-activated B cells

    A

  • 4

    4. T cells travel from bone marrow to the thymus for maturation. What is the correct order of the maturation sequence for T cells in the thymus? * 1/1 A. Bone marrow to the cortex; after thymic education, released back to peripheral circulation B. Maturation and selection occur in the cortex; migration to the medulla; release of mature T cells to secondary lymphoid organs C. Storage in either the cortex or medulla; release of T cells into the peripheral circulation D. Activation and selection occur in the medulla; mature T cells are stored in the cortex until activated by antigen

    B

  • 5

    5. Which cluster of differentiation (CD) marker is the most specific identifying marker for mature T cells? * 1/1 A. CD1 B. CD2 C. CD3 D. CD4 or CD8

    C

  • 6

    Which markers are found on mature, peripheral helper T cells? * 1/1 A. CD1, CD2, CD4 B. CD2, CD3, CD8 C. CD1, CD3, CD4 D. CD2, CD3, CD4

    D

  • 7

    . Which T cells express the CD8 marker and act specifically to kill tumors or virally infected cells? * 1/1 A. Helper T cells B. Suppressor T cells C. Cytotoxic T cells (TC cells) D. Regulator T cells

    C

  • 8

    8. How are TC cells and natural killer (NK) cells similar? * 1/1 A. Require antibody to be present B. Effective against virally infected cells C. Recognize antigen in association with human leukocyte antigen (HLA) class II markers D. Do not bind to infected cells

    B

  • 9

    9. What is the name of the process by which phagocytic cells are attracted to a substance, such as a bacterial peptide? * 1/1 A. Diapedesis B. Degranulation C. Chemotaxis D. Phagotaxis

    C

  • 10

    10. All of the following are immunologic functions of complement except: * 1/1 A. Induction of an antiviral state B. Opsonization C. Chemotaxis D. Anaphylatoxin formation

    A

  • 11

    11. Which complement component is found in both the classic and alternative pathways? * 1/1 A. C1 B. C4 C. Factor D D. C3

    D

  • 12

    12. Which Ig(s) help(s) initiate the classic complement pathway? * 1/1 A. IgA and IgD B. IgM only C. IgG and IgM D. IgG only

    C

  • 13

    13. How is complement activity destroyed in vitro? * 1/1 A. Heating serum at 56°C for 30 minutes B. Keeping serum at room temperature of 22°C for 1 hour C. Heating serum at 37°C for 45 minutes D. Freezing serum at 0°C for 24 hours

    A

  • 14

    14. What is the purpose of C3a, C4a, and C5a, the split products of the complement cascade? * 0/1 A. To bind with specific membrane receptors of lymphocytes and cause release of cytotoxic substances B. To cause increased vascular permeability, contraction of smooth muscle, and release of histamine from basophils C. To bind with membrane receptors of macrophages to facilitate phagocytosis and the removal of debris and foreign substances D. To regulate and degrade membrane cofactor protein after activation by C3 convertase

    B

  • 15

    15. Which region of the Ig molecule can bind antigen? * 1/1 A. Fragment antigen binding (Fab) B. Fragment crystallizable (Fc) C. Constant light (CL) D. Constant heavy (CH)

    A

  • 16

    16. Which region determines whether an Ig molecule can fix complement? * 0/1 A. Variable heavy (VH) B. Constant heavy (CH) C. Variable light (VL) D. Constant light (CL)

    B

  • 17

    17. Which Ig class(es) has (have) a J-chain? * 1/1 A. IgM B. IgE and IgD C. IgM and surface IgA (sIgA) D. IgG3 and IgA

    C

  • 18

    18. Which Ig appears first in the primary immune response? * 1/1 A. IgG B. IgM C. IgA D. IgE

    B

  • 19

    19. Which immunoglobulin appears in highest titer in the secondary response? * 0/1 A. IgG B. IgM C. IgA D. IgE

    A

  • 20

    20. Which Ig can cross the placenta? * 1/1 A. IgG B. IgM C. IgA D. IgE

    A

  • 21

    21. Which Ig cross-links mast cells to release histamine? * 1/1 A. IgG B. IgM C. IgA D. IgE

    D

  • 22

    22. All of the following are functions of Igs except: * 0/1 A. Neutralizing toxic substances B. Facilitating phagocytosis through opsonization C. Interacting with TC cells to lyse viruses D. Combining with complement to destroy cellular antigens

    C

  • 23

    23. Which of the following cell surface molecules is classified as an MHC class II antigen? * 1/1 A. HLA-A B. HLA-B C. HLA-C D. HLA-DR

    D

  • 24

    24. Which MHC class of molecule is necessary for antigen recognition by CD4-positive T cells? * 1/1 A. Class I B. Class II C. Class III D. No MHC molecule is necessary for antigen recognition

    B

  • 25

    25. Which of the following are products of HLA class III genes? * 1/1 A. T-cell immune receptors B. HLA-D antigens on immune cells C. Complement proteins C2, C4, and factor B D. Ig VL regions

    C

  • 26

    26. What molecule on the surface of most T cells recognizes antigen? * 1/1 A. IgT, a four-chain molecule that includes the tau heavy chain B. MHC protein, a two-chain molecule encoded by the HLA region C. CD3, consisting of six different chains D. T-cell receptor (TcR), consisting of two chains: α-chain and β-chain

    D

  • 27

    27. TcR is similar to Ig molecules in that it: * 0/1 A. Remains bound to the cell surface and is never secreted B. Contains V and C regions on each of its chains C. Binds complement D. Can cross the placenta and provide protection to a fetus

    B

  • 28

    28. Toll-like receptors (TLRs) are found on which cells? * 1/1 A. T cells B. Dendritic cells C. B cells D. Large granular lymphocytes

    B

  • 29

    29. Macrophages produce which of the following proteins during antigen processing? * 1/1 A. IL-1 and IL-6 B. γ-Interferon C. IL-4, IL-5, and IL-10 D. Complement components C1 and C3

    A

  • 30

    30. A superantigen, such as toxic shock syndrome toxin-1 (TSST-1), bypasses the normal antigen-processing stage by binding to and cross-linking: * 1/1 A. A portion of an Ig molecule and complement component C1 B. TLRs and an MHC class 1 molecule C. A portion of an Ig and a portion of a TcR D. A portion of a TcR and an MHC class II molecule

    D

  • 31

    31. T-regulator cells, responsible for controlling autoimmune antibody production, express which of the following phenotypes? * 0/1 A. CD3, CD4, CD8 B. CD3, CD8, CD25 C. CD3, CD4, CD25 D. CD8, CD25, CD56

    C

  • 32

    1. The interaction between individual antigen and antibody molecules depends on several types of bonds, such as ionic bonds, hydrogen bonds, hydrophobic bonds, and van der Waals forces. How is the strength of this attraction characterized? * 1/1 A. Avidity B. Affinity C. Reactivity D. Valency

    B

  • 33

    2. A laboratory is evaluating an enzyme-linked immunosorbent assay (ELISA) for detecting an antibody to cyclic citrullinated peptide (CCP), which is a marker for rheumatoid arthritis (RA). The laboratory includes serum from healthy volunteers and from patients with other connective tissue diseases in the evaluation. These specimens determine which factor of the assay? * 1/1 A. Sensitivity B. Precision C. Bias D. Specificity

    D

  • 34

    3. The detection of precipitation reactions depends on the presence of optimal proportions of antigen and antibody. A patient’s sample contains a large amount of antibody, but the reaction in a test system containing antigen is negative. What has happened? * 1/1 A. Performance error B. Low specificity C. A shift in the zone of equivalence D. Prozone phenomenon

    D

  • 35

    4. The positive and negative control values for an ELISA procedure are below their acceptable ranges. What is the most likely cause? * 0/1 A. Decay of the positive and negative controls B. Incomplete washing following specimen addition C. Overly long incubation times D. Decay of the antibody–enzyme conjugate

    D

  • 36

    5. What is the interpretation when an Ouchterlony plate shows crossed lines between wells 1 and 2 (antigen is placed in the center well and antisera in wells 1 and 2)? * 1/1 A. No reaction between wells 1 and 2 B. Partial identity between wells 1 and 2 C. Nonidentity between wells 1 and 2 D. Identity between wells 1 and 2

    C

  • 37

    6. A weight lifter taking many supplements is tested monthly for thyroid-stimulating hormone (TSH) in a direct capture assay, which uses a streptavidin–biotin indicator system. She has had normal TSH levels for the past 3 months on specimens collected in the late evening. This month she comes in right after breakfast for her blood draw. The TSH level is three times her previous level. What may be the cause of this difference? * 0/1 A. Diurnal variation in TSH levels B. Exogenous biotin in her system from a supplement taken that morning C. Reduced thyroid function caused by an unidentified pathology D. Pipetting error

    B

  • 38

    7. What comprises the indicator system in an indirect ELISA for detecting antibody? * 0/1 A. Enzyme-conjugated antibody + chromogenic substrate B. Enzyme conjugated antigen + chromogenic substrate C. Enzyme + antigen D. Substrate + antigen

    A

  • 39

    8. What outcome results from improper washing of a tube or well after adding the enzyme–antibody conjugate in an ELISA system? * 1/1 A. Result will be falsely decreased B. Result will be falsely increased C. Result will be unaffected D. Result is impossible to determine

    A

  • 40

    9. What would happen if the color reaction phase is prolonged in one tube or well of an ELISA test? * 1/1 A. Result will be falsely decreased B. Result will be falsely increased C. Result will be unaffected D. Impossible to determine

    B

  • 41

    10. The absorbance of a sample measured by ELISA is greater than the highest standard. What corrective action should be taken? * 1/1 A. Extrapolate an estimated value from the highest reading B. Repeat the test using a standard of higher concentration C. Repeat the assay using one half the volume of the sample D. Dilute the test sample

    D

  • 42

    11. A patient was suspected of having a lymphoproliferative disorder. After several laboratory tests were completed, the patient was found to have an IgMκ paraprotein. In what sequence should the laboratory tests leading to this diagnosis have been performed? * 1/1 A. Serum protein electrophoresis (SPE) followed by immunofixation electrophoresis (IFE) B. Ig levels, followed by SPE C. Total lymphocyte count, followed by Ig levels D. Ig levels, followed by urine protein electrophoresis

    A

  • 43

    12. An IFE performed on a serum sample showed a narrow dark band in the lanes containing anti-γ and anti-λ. How should this result be interpreted? * 1/1 A. Abnormally decreased IgG concentration B. Abnormal test result demonstrating monoclonal IgGλ C. Normal test result D. Impossible to determine without densitometric quantitation

    B

  • 44

    13. Which type of nephelometry is used to measure immune complex formation almost immediately after reagent has been added? * 0/1 A. Rate B. Endpoint C. Continuous D. One-dimensional

    A

  • 45

    14. An antinuclear antibody (ANA) test was performed by using immunofluorescence microscopy assay (IFA), and a clinically significant pattern and titer were reported. Positive and negative controls performed as expected. However, the clinical evaluation of the patient was not consistent with the reported pattern. What is the most likely explanation for this situation? * 0/1 A. The clinical condition of the patient changed since the sample was tested B. The pattern of fluorescence was misinterpreted C. The control results were misinterpreted D. The wrong cell line was used for the test

    B

  • 46

    15. What corrective action should be taken when a specific pattern cannot be identified in a specimen with a positive ANA IFA? * 1/1 A. Repeat the test using a larger volume of sample B. Call the physician C. Have another medical laboratory scientist read the slide D. Dilute the sample and retest

    D

  • 47

    16. Which statement best describes passive agglutination reactions used for serodiagnosis? * 1/1 A. Such agglutination reactions are more rapid because they are a single-step process B. Reactions require the addition of a second antibody C. Passive agglutination reactions require biphasic incubation D. Carrier particles for antigen, such as latex particles, are used

    D

  • 48

    17. What has happened in a titer, if tube Nos. 5 to 7 show a stronger reaction than tube Nos.1 to 4? * 1/1 A. Prozone reaction B. Postzone reaction C. Equivalence reaction D. Poor technique

    A

  • 49

    18. What is the titer in tube No. 8 if tube No. 1 is undiluted and dilutions are doubled? * 0/1 A. 64 B. 128 C. 256 D. 512

    B

  • 50

    9. The directions for a slide agglutination test instruct that after mixing the patient’s serum and antigen-coated latex particles, the slide must be rotated for 2 minutes. What would happen if the slide were rotated for 10 minutes? * 0/1 A. Possible false-positive result B. Possible false-negative result C. No effect D. Depends on the amount of antibody present in

    A

  • 51

    20. Which outcome indicates a negative result in a complement fixation test? * 0/1 A. Hemagglutination B. Absence of hemagglutination C. Hemolysis D. Absence of hemolysis

    C

  • 52

    21. What effect does selecting the wrong gate have on the results when cells are counted by flow cytometry? * 0/1 A. No effect B. Failure to count the desired cell population C. Falsely elevated results D. Impossible to determine

    B

  • 53

    22. Which statement best describes immunophenotyping? * 0/1 A. Lineage determination by detecting antigens on the surface of the gated cells by using fluorescent antibodies B. Identification of cell maturity by using antibodies to detect antigens within the nucleus C. Identification and sorting of cells by front and side scatter of light from a laser D. Analysis of cells collected by flow cytometry by using traditional agglutination reactions

    A

  • 54

    23. A flow cytometry scattergram of a bone marrow sample shows a dense population of cells located in-between normal lymphoid and normal myeloid cells. What is the most likely explanation? * 0/1 A. The sample was improperly collected B. An abnormal cell population is present C. The laser optics are out of alignment D. The cells are most likely not leukocytes

    B

  • 55

    1. Which serum antibody response usually characterizes the primary (early) stage of syphilis? * 1/1 A. Antibodies against syphilis are undetectable B. Detected 1 to 3 weeks after appearance of the primary chancre C. Detected in 50% of cases before the primary chancre disappears D. Detected within 2 weeks after infection

    B

  • 56

    2. What substance is detected in the sample by the rapid plasma reagin (RPR) and Venereal Disease Research Laboratory (VDRL) tests for syphilis? * 0/1 A. Cardiolipin B. Anticardiolipin antibody (ACA) C. Anti–Treponema pallidum antibody D. T. pallidum

    B

  • 57

    3. What type of antigen is used in the RPR card test? * 1/1 A. Live treponemal organisms B. Killed suspension of treponemal organisms C. Cardiolipin D. Tanned sheep cells

    C

  • 58

    4. Which of the following is the most sensitive test to detect congenital syphilis? * 1/1 A. VDRL B. RPR C. T. pallidum particle agglutination (TP-PA) D. Polymerase chain reaction (PCR)

    D

  • 59

    5. A biological false-positive reaction is least likely with which test for syphilis? * 1/1 A. VDRL B. TP-PA C. RPR D. All are equally likely to yield a false-positive result

    B

  • 60

    6. A 12-year old girl has symptoms of fatigue and localized lymphadenopathy. Laboratory tests reveal peripheral blood lymphocytosis, positive RPR, and positive spot test for IM. What test should be performed next? * 0/1 A. HIV screen B. VDRL C. Epstein-Barr virus (EBV)–specific antigen test D. TP-PA test

    D

  • 61

    7. Which test is most likely to be positive in the tertiary stage of syphilis? * 0/1 A. Treponemal-specific antibody B. RPR C. VDRL D. Reagin screen test (RST)

    a

  • 62

    8. What is the most likely interpretation of the following syphilis serological results? RPR: reactive; TP-PA: nonreactive * 0/1 A. Neurosyphilis B. Secondary syphilis C. Syphilis that has been successfully treated D. Biological false positive

    D

  • 63

    9. Which specimen is the sample of choice to evaluate latent or tertiary syphilis? * 1/1 A. Serum sample B. Chancre fluid C. Cerebrospinal fluid (CSF) D. Joint fluid

    C

  • 64

    10. Interpret the following quantitative RPR test results. RPR titer: weakly reactive—1:4; reactive—1:8 to 1:64 * 0/1 A. Excess antibody, prozone effect B. Excess antigen, postzone effect C. Equivalence of antigen and antibody D. Impossible to interpret; testing error

    A

  • 65

    11. Tests to identify infection with HIV fall into which three general classification types of tests? * 0/1 A. Tissue culture, antigen, and antibody tests B. Tests for antigens, antibodies, and nucleic acid C. DNA probe, DNA amplification, and Western blot tests D. ELISA, Western blot, and Southern blot tests

    B

  • 66

    12. Which tests are considered screening tests for HIV? * 1/1 A. ELISA, chemiluminescent, and rapid antibody tests B. IFA, Western blot, radioimmunoprecipitation assay C. Culture, antigen capture assay, DNA amplification D. Reverse transcriptase and messenger RNA (mRNA) assay

    A

  • 67

    13. Which tests are the recommended confirmatory tests for HIV? * 1/1 A. ELISA and rapid antibody tests B. HIV-1,2 antibody differentiation assays, and qualitative PCR test C. Culture, antigen capture assay, quantitative PCR D. Reverse transcriptase and mRNA assay

    B

  • 68

    14. How do fourth- and fifth-generation HIV tests reduce the time from infection to the test becoming positive? * 1/1 A. They are PCR tests detecting viral RNA B. They detect p24 antigen in addition to HIV antibody C. They detect proviral DNA D. They detect antibodies to more antigens than earlier generations of HIV tests

    B

  • 69

    15. A woman who has had five pregnancies subsequently tests positive for HIV on a fourth-generation assay and is negative on an HIV-1,2 differentiation assay and a follow-up molecular assay. The initial reactivity may be caused by: * 1/1 A. Possible cross-reaction with herpes or EBV antibodies B. Interference from medication C. Cross-reacting antibodies elicited during pregnancy D. Possible technical error; a repeat specimen should be requested

    C

  • 70

    16. Interpret the following results for HIV testing: Fourth-generation ELISA: positive; repeat ELISA: positive; HIV 1,2 antibody differentiation assay: negative; qualitative HIV RNA rtPCR assay: positive * 1/1 A. False-positive fourth-generation assay B. False-negative antibody differentiation assay C. Indeterminate; further testing indicated D. HIV p24 antigen detected on fourth-generation ELISA

    D

  • 71

    17. What is the most likely explanation when antibody tests for HIV are negative but the PCR test is positive? * 1/1 A. Probably not HIV infection B. Patient is in the “window phase” before antibody production C. Tests were performed incorrectly D. Clinical signs may be misinterpreted

    B

  • 72

    18. What criteria constitute the classification system for HIV infection? * 1/1 A. CD4-positive T-cell count and clinical symptoms B. Clinical symptoms, condition, duration, and strength of reactivity on a fourth-generation HIV test C. Presence or absence of lymphadenopathy D. Strong fourth-generation HIV test reactivity and CD8-positive T-cell count

    A

  • 73

    19. What is the main difficulty associated with the development of an HIV vaccine? * 1/1 A. The virus has been difficult to culture; antigen extraction and concentration are extremely laborious B. Human trials cannot be performed C. Different strains of the virus are genetically diverse D. Anti-idiotype antibodies cannot be developed

    C

  • 74

    20. Which CD4:CD8 ratio is most likely in a patient with AIDS? * 0/1 A. 2:1 B. 3:1 C. 2:3 D. 1:3

    D

  • 75

    21. What is the advantage of fourth-generation rapid HIV tests over earlier rapid HIV tests? * 1/1 A. They use recombinant antigens B. They detect multiple strains of HIV C. They detect p24 antigen D. They are quantitative

    C

  • 76

    22. Which method is used to test for HIV infection in infants who are born to HIV-positive mothers? * 1/1 A. ELISA B. Western blot test C. PCR test D. Viral culture

    C

  • 77

    23. What is the most likely cause when a fourth-generation HIV assay is positive for all controls and samples? * 0/1 A. Improper pipetting B. Improper washing C. Improper addition of sample D. Improper reading

    B

  • 78

    24. What constitutes a diagnosis of viral hepatitis? * 1/1 A. Abnormal test results for liver enzymes B. Clinical signs and symptoms C. Positive results for hepatitis markers D. All of these options

    D

  • 79

    25. Which of the following statements regarding infection with hepatitis D virus (HDV) is true? * 0/1 A. Occurs in patients with HIV infection B. Does not progress to chronic hepatitis C. Occurs in patients with hepatitis B virus (HBV) infection D. Is not spread through blood or sexual contact

    C

  • 80

    26. All of the following hepatitis viruses are spread through blood or blood products except: * 1/1 A. Hepatitis A virus (HAV) B. HBV C. HCV D. HDV

    A

  • 81

    27. Which hepatitis B marker is the best indicator of early acute infection? * 1/1 A. Hepatitis B surface antigen (HBsAg) B. Hepatitis B e-antigen (HBeAg) C. Hepatitis B core antibody (anti-HBc) D. Hepatitis B surface antibody (anti-HBs)

    A

  • 82

    28. Which is the first antibody detected in serum after infection with HBV? * 1/1 A. Anti-HBs B. Anti-HBc IgM C. Anti-HBe D. All are detectable at the same time

    B

  • 83

    29. Which antibody persists in low-level carriers of HBV? * 0/1 A. IgM anti-HBc B. IgG anti-HBc C. IgM anti-HBe D. IgG anti-HBs

    B

  • 84

    30. What is the most likely explanation when a patient has clinical signs of viral hepatitis but tests negative for HAV IgM, HBsAg, and HCV antibody? * 1/1 A. Tests were performed improperly B. The patient does not have hepatitis C. The patient may be in the “core window” D. Clinical evaluation was performed improperly

    C

  • 85

    31. Which hepatitis B markers should be performed on blood products? * 1/1 A. HBsAg and anti-HBc B. Anti-HBs and anti-HBc C. HBeAg and HBcAg D. Anti-HBs and HBeAg

    A

  • 86

    32. Which hepatitis antibody confers immunity against reinfection with HBV? * 0/1 A. Anti-HBc IgM B. Anti-HBc IgG C. Anti-HBe D. Anti-HBs

    D

  • 87

    33. Which test, other than serological markers, is most consistently elevated in viral hepatitis? * 0/1 A. Antinuclear antibodies B. Alanine aminotransferase (ALT) C. Absolute lymphocyte count D. Lactate dehydrogenase

    B

  • 88

    34. If only anti-HBs is positive, which of the following can be ruled out? * 0/1 A. HBV vaccination B. Distant past infection with HBV C. Hepatitis B immune globulin (HBIG) injection D. Chronic HBV infection

    D

  • 89

    35. Interpret the following results for EBV infection: IgG and IgM antibodies to viral capsid antigen (VCA) are positive. * 0/1 A. Infection in the past B. Infection with a mutual enhancer virus, such as HIV C. Current infection D. Impossible to interpret; need more information

    C

  • 90

    36. Rapid mono tests use latex particles coated with which of the following? * 0/1 A. Guinea pig antigen B. Beef proteins C. Horse proteins D. Sheep proteins

    B

  • 91

    37. Blood products are tested for which virus before being transfused to newborns? * 1/1 A. EBV B. Human T-lymphotropic virus II (HTLV-II) C. CMV D. HDV

    C

  • 92

    38. What is the endpoint for the antistreptolysin O (ASO) latex agglutination assay? * 1/1 A. Highest serum dilution that shows no agglutination B. Highest serum dilution that shows agglutination C. Lowest serum dilution that shows agglutination D. Lowest serum dilution that shows no agglutination

    B

  • 93

    39. A streptozyme test was performed, but the result was negative, even though the patient showed clinical signs of a streptococcal throat infection. What should be done next? * 1/1 A. Either ASO or anti-deoxyribonuclease B (anti-DNase B) test B. Another streptozyme test using diluted serum C. Antihyaluronidase test D. Wait for 3 to 5 days and repeat the streptozyme test

    A

  • 94

    40. Rapid assays for influenza that utilize specimens obtained from nasopharyngeal swabs detect: * 0/1 A. IgM anti-influenza B. IgA anti-influenza C. IgA–influenza antigen immune complexes D. Influenza nucleoprotein antigens

    D

  • 95

    41. How can interfering cold agglutinins be removed from a test sample? * 0/1 A. Centrifuge the serum and remove the top layer B. Incubate the clot at 1°C to 4°C for several hours and then remove the serum C. Incubate the serum at 56°C in a water bath for 30 minutes D. Use an anticoagulated sample

    B

  • 96

    42. All tubes (dilutions) except the negative control are positive for cold agglutinins. This indicates: * 0/1 A. Contaminated RBCs B. A rare antibody against RBC antigens C. The sample was stored at 4°C prior to separating serum and cells D. Further serial dilution is necessary

    D

  • 97

    43. All positive cold agglutinin tubes remain positive after 37°C incubation except the positive control. What is the most likely explanation for this situation? * 0/1 A. High-titer cold agglutinins B. Contamination of the test system C. Antibody other than cold agglutinins D. Faulty water bath

    C

  • 98

    44. Which increase in antibody titer (dilution) best indicates an acute infection? * 1/1 A. From 1:2 to 1:8 B. From 1:4 to 1:16 C. From 1:16 to 1:256 D. From 1:64 to 1:128

    C

  • 99

    45. Which of the following positive antibody tests may be an indication of recent vaccination or early primary infection for rubella in a patient with no clinical symptoms? * 1/1 A. Only IgG antibodies positive B. Only IgM antibodies positive C. Both IgG and IgM antibodies positive D. Fourfold rise in titer for IgG antibodies

    B

  • 100

    46. Why is laboratory diagnosis difficult in cases of Lyme disease? * 0/1 A. Clinical response may not be apparent upon initial infection; IgM antibody may not be detected until 3 to 6 weeks after the infection. B. Laboratory tests may be designed to detect whole Borrelia burgdorferi, not flagellar antigen found early in infection C. Most laboratory tests are technically demanding and lack specificity D. Antibodies formed initially to B. burgdorferi may cross react in antigen tests for autoimmune diseases

    A